US-based Tryton Medical has received CE Mark for its side-branch stent for the treatment of left main coronary artery disease.

According to the company, approval makes it the only coronary bifurcation stent cleared in Europe for the left main indication.

Left main disease is an accumulation of plaque that narrows the base of the coronary tree. There are approximately 200,000 cardiac surgeries performed in left main annually.

In May 2013, Tryton side branch short stent was approved in the European Union increasing the number of treatment options in large vessel bifurcations associated with a short main branch landing zone.

"Obtaining CE Mark approval for the left main indication significantly expands the market opportunity for our stent platform."

Erasmus MC (Rotterdam, the Netherlands) Dr Robert-Jan van Geuns said a predictable and safe outcome is essential for the treatment of this high-risk population.

"The Tryton side branch stent provides the necessary control in each step of the procedure," Dr Geuns said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"With the launch last summer of the Tryton SHORT stent, the expansive range of Tryton stents allows me to definitively treat the vast majority of my left main bifurcation lesions cases with a predictable procedure and durable result."

The Tryton side branch stent is currently available for sale in Europe and parts of the Middle East, is investigational in the US, and is not available in Japan.

The device was developed based on the company’s proprietary, first-in-class Tri-ZONE technology.

It offers a dedicated strategy for treating bifurcation lesions and is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

Tryton Medical CEO Shawn McCarthy said: "Obtaining CE Mark approval for the left main indication significantly expands the market opportunity for our stent platform.

"As market leaders, we continue to invest and introduce meaningful product innovation, clinical evidence, and physician education, to advance the standard of care for bifurcated coronary artery disease."